Charles River Laboratories International (CRL) Total Debt (2009 - 2026)
Charles River Laboratories International (CRL) posted Total Debt of $2.6 billion for Q2 2026, down 1.62% on a QoQ basis from $2.7 billion in Q1 2026, and up 12.33% year-over-year from $2.3 billion in Q2 2025.
Analysis
Charles River Laboratories International (CRL) Total Debt (2009 - 2026) Analysis & Trends
Charles River Laboratories International has reported Total Debt for 18 years, with the latest figure at $2.6 billion in Q2 2026.
- On a quarterly basis, Total Debt rose 12.33% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 12.33% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, down 4.64% from the prior year.
- Total Debt was $2.6 billion for Q2 2026 at Charles River Laboratories International, down from $2.7 billion in the prior quarter.
- The five-year high for Total Debt was $3.0 billion in Q2 2022, with the low at $2.1 billion in Q4 2025.
- Average Total Debt over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2023.
- The sharpest annual moves came in 2022 and 2024: Total Debt advanced 21.47% in 2022, then fell 15.37% in 2024.
- Over 5 years, Total Debt stood at $2.7 billion in 2022, then declined by 2.23% to $2.6 billion in 2023, then retreated by 15.37% to $2.2 billion in 2024, then dropped by 4.64% to $2.1 billion in 2025, then climbed by 22.64% to $2.6 billion in 2026.
- The last three Total Debt figures came in at $2.6 billion (Q2 2026), $2.7 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 16.00 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 3.39 Bn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 2.62 Bn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 1.05 Bn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 553.13 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | - |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 2.62 Bn |
| Mar 28, 2026 | 2.66 Bn |
| Dec 27, 2025 | 2.14 Bn |
| Sep 27, 2025 | 2.19 Bn |
| Jun 28, 2025 | 2.33 Bn |
| Mar 29, 2025 | 2.51 Bn |
| Dec 28, 2024 | 2.24 Bn |
| Sep 28, 2024 | 2.33 Bn |
| Jun 29, 2024 | 2.41 Bn |
| Mar 30, 2024 | 2.66 Bn |
| Dec 30, 2023 | 2.65 Bn |
| Sep 30, 2023 | 2.51 Bn |
| Jul 1, 2023 | 2.68 Bn |
| Apr 1, 2023 | 2.74 Bn |
| Dec 31, 2022 | 2.71 Bn |
| Sep 24, 2022 | 2.94 Bn |
| Jun 25, 2022 | 3.00 Bn |
| Mar 26, 2022 | 2.68 Bn |
| Dec 25, 2021 | 2.67 Bn |
| Sep 25, 2021 | 2.89 Bn |